SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors

Abstract Introduction The COVID‐19 vaccine was designed to provide protection against infection by the severe respiratory coronavirus 2 (SARS‐CoV‐2) and coronavirus disease 2019 (COVID‐19). However, the vaccine's efficacy can be compromised in patients with immunodeficiencies or the vaccine‐ind...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pavla Taborska, Jan Lastovicka, Dmitry Stakheev, Zuzana Strizova, Jirina Bartunkova, Daniel Smrz
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	cellular immunity COVID‐19 vaccination ex vivo expansion humoral immunity SARS‐CoV‐2 spike glycoprotein‐reactive Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/c76674d72c464dc19ea0dc2ddfead6dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c76674d72c464dc19ea0dc2ddfead6dd
record_format	dspace
spelling	oai:doaj.org-article:c76674d72c464dc19ea0dc2ddfead6dd2021-11-12T19:57:15ZSARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors2050-452710.1002/iid3.496https://doaj.org/article/c76674d72c464dc19ea0dc2ddfead6dd2021-12-01T00:00:00Zhttps://doi.org/10.1002/iid3.496https://doaj.org/toc/2050-4527Abstract Introduction The COVID‐19 vaccine was designed to provide protection against infection by the severe respiratory coronavirus 2 (SARS‐CoV‐2) and coronavirus disease 2019 (COVID‐19). However, the vaccine's efficacy can be compromised in patients with immunodeficiencies or the vaccine‐induced immunoprotection suppressed by other comorbidity treatments, such as chemotherapy or immunotherapy. To enhance the protective role of the COVID‐19 vaccine, we have investigated a combination of the COVID‐19 vaccination with ex vivo enrichment and large‐scale expansion of SARS‐CoV‐2 spike glycoprotein‐reactive CD4+ and CD8+ T cells. Methods SARS‐CoV‐2‐unexposed donors were vaccinated with two doses of the BNT162b2 SARS‐CoV‐2 vaccine. The peripheral blood mononuclear cells of the vaccinated donors were cell culture‐enriched with T cells reactive to peptides derived from SARS‐CoV‐2 spike glycoprotein. The enriched cell cultures were large‐scale expanded using the rapid expansion protocol (REP) and the peptide‐reactive T cells were evaluated. Results We show that vaccination with the SARS‐CoV‐2 spike glycoprotein‐based mRNA COVID‐19 vaccine‐induced humoral response against SARS‐CoV‐2 spike glycoprotein in all tested healthy SARS‐CoV‐2‐unexposed donors. This humoral response was found to correlate with the ability of the donors' PBMCs to become enriched with SARS‐CoV‐2 spike glycoprotein‐reactive CD4+ and CD8+ T cells. Using an 11‐day REP, the enriched cell cultures were expanded nearly 1000‐fold, and the proportions of the SARS‐CoV‐2 spike glycoprotein‐reactive T cells increased. Conclusion These findings show for the first time that the combination of the COVID‐19 vaccination and ex vivo T cell large‐scale expansion of SARS‐CoV‐2‐reactive T cells could be a powerful tool for developing T cell‐based adoptive cellular immunotherapy of COVID‐19.Pavla TaborskaJan LastovickaDmitry StakheevZuzana StrizovaJirina BartunkovaDaniel SmrzWileyarticlecellular immunityCOVID‐19 vaccinationex vivo expansionhumoral immunitySARS‐CoV‐2spike glycoprotein‐reactiveImmunologic diseases. AllergyRC581-607ENImmunity, Inflammation and Disease, Vol 9, Iss 4, Pp 1452-1467 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cellular immunity COVID‐19 vaccination ex vivo expansion humoral immunity SARS‐CoV‐2 spike glycoprotein‐reactive Immunologic diseases. Allergy RC581-607
spellingShingle	cellular immunity COVID‐19 vaccination ex vivo expansion humoral immunity SARS‐CoV‐2 spike glycoprotein‐reactive Immunologic diseases. Allergy RC581-607 Pavla Taborska Jan Lastovicka Dmitry Stakheev Zuzana Strizova Jirina Bartunkova Daniel Smrz SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
description	Abstract Introduction The COVID‐19 vaccine was designed to provide protection against infection by the severe respiratory coronavirus 2 (SARS‐CoV‐2) and coronavirus disease 2019 (COVID‐19). However, the vaccine's efficacy can be compromised in patients with immunodeficiencies or the vaccine‐induced immunoprotection suppressed by other comorbidity treatments, such as chemotherapy or immunotherapy. To enhance the protective role of the COVID‐19 vaccine, we have investigated a combination of the COVID‐19 vaccination with ex vivo enrichment and large‐scale expansion of SARS‐CoV‐2 spike glycoprotein‐reactive CD4+ and CD8+ T cells. Methods SARS‐CoV‐2‐unexposed donors were vaccinated with two doses of the BNT162b2 SARS‐CoV‐2 vaccine. The peripheral blood mononuclear cells of the vaccinated donors were cell culture‐enriched with T cells reactive to peptides derived from SARS‐CoV‐2 spike glycoprotein. The enriched cell cultures were large‐scale expanded using the rapid expansion protocol (REP) and the peptide‐reactive T cells were evaluated. Results We show that vaccination with the SARS‐CoV‐2 spike glycoprotein‐based mRNA COVID‐19 vaccine‐induced humoral response against SARS‐CoV‐2 spike glycoprotein in all tested healthy SARS‐CoV‐2‐unexposed donors. This humoral response was found to correlate with the ability of the donors' PBMCs to become enriched with SARS‐CoV‐2 spike glycoprotein‐reactive CD4+ and CD8+ T cells. Using an 11‐day REP, the enriched cell cultures were expanded nearly 1000‐fold, and the proportions of the SARS‐CoV‐2 spike glycoprotein‐reactive T cells increased. Conclusion These findings show for the first time that the combination of the COVID‐19 vaccination and ex vivo T cell large‐scale expansion of SARS‐CoV‐2‐reactive T cells could be a powerful tool for developing T cell‐based adoptive cellular immunotherapy of COVID‐19.
format	article
author	Pavla Taborska Jan Lastovicka Dmitry Stakheev Zuzana Strizova Jirina Bartunkova Daniel Smrz
author_facet	Pavla Taborska Jan Lastovicka Dmitry Stakheev Zuzana Strizova Jirina Bartunkova Daniel Smrz
author_sort	Pavla Taborska
title	SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
title_short	SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
title_full	SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
title_fullStr	SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
title_full_unstemmed	SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
title_sort	sars‐cov‐2 spike glycoprotein‐reactive t cells can be readily expanded from covid‐19 vaccinated donors
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/c76674d72c464dc19ea0dc2ddfead6dd
work_keys_str_mv	AT pavlataborska sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors AT janlastovicka sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors AT dmitrystakheev sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors AT zuzanastrizova sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors AT jirinabartunkova sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors AT danielsmrz sarscov2spikeglycoproteinreactivetcellscanbereadilyexpandedfromcovid19vaccinateddonors
_version_	1718430341286330368

SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors

Ejemplares similares